From May 16 through May 20, the American Psychiatric Association (APA) hosted its 2026 annual conference in San Francisco, California. Each year, the APA Annual Meeting emphasizes practical, evidence-based approaches to navigating complex clinical and professional landscapes, offering workshops, discussions, and shared strategies designed to benefit psychiatrists and other mental health professionals.

Today’s recap features a curated selection of posters on topics related to schizophrenia. Some descriptions and conclusions have been edited for clarity or brevity. To view all the posters presented at the 2026 APA Annual Meeting, view the 2026 posters archive.

Discordant by Design: A Twin Study Review of Prematurity and Antipsychotic Exposure in Schizophrenia Trajectories

  • Description: Monozygotic (MZ) twin pairs discordant for schizophrenia represent a unique natural experiment to isolate environmental and iatrogenic contributions to disease onset, severity, and treatment resistance. This systematic review synthesizes findings from twin studies to investigate how prematurity and differential antipsychotic exposure shape divergent psychotic illness trajectories in genetically matched individuals.
  • Conclusion: By controlling for genetic confounders, twin studies provide compelling evidence that prematurity and treatment duration are independent modifiers of schizophrenia trajectory. This review demonstrates that divergent outcomes in genetically identical twins reflect differential neurodevelopmental insults and iatrogenic adaptations, not just stochastic factors. These findings advocate for twin-informed research designs to develop neuroprotective strategies for preterm populations and to optimize timing and duration of antipsychotic treatment to mitigate potential long-term neuroadaptive effects.

When First-Line Fails: Electroconvulsive Therapy versus Clozapine in Schizoaffective Disorder and Treatment-Resistant Schizophrenia

  • Description: Schizoaffective disorder and schizophrenia present significant therapeutic challenges in psychiatry. While clozapine is the most studied medication in treatment resistance, there is a large portion of the population that remains refractory to treatment. Electroconvulsive therapy (ECT) is increasingly utilized for augmentation; however, there are limited amounts of direct comparisons of efficacy, safety, and long-term outcomes of ECT and clozapine.
  • Conclusion: While clozapine remains the first-line treatment for treatment-resistant psychosis in schizophrenia and schizoaffective disorder, ECT is a safe and effective augmentation and may allow for alternate treatment option for care. While ECT with maintenance therapy demonstrates both favorable short-term benefits in head-to-head trials and evidence of positive long-term cognitive and functional outcomes, there are imitations for common use as a monotherapy. Specifically, the current data are limited through small sample sizes, heterogeneity in study design, and relative lack of long-term data.

Efficacy and Safety of LB-102 for Acute Schizophrenia: A Secondary Analysis of Positive Symptoms

  • Description: LB-102 is a novel D2/D3/5-HT7 antagonist in development for schizophrenia. Preclinical assays showed similar receptor binding, pharmacokinetics, and behavioral modification properties between LB-102 and amisulpride. A human dopamine receptor occupancy study showed LB-102 50mg daily exhibited similar receptor occupancy to amisulpride 400mg. A phase 1 trial in healthy volunteers demonstrated LB-102 had an acceptable safety profile up to 150mg/day.
  • Conclusion: This phase 2 clinical trial provided robust evidence on the efficacy and safety of LB-102 for the treatment of adults with acute schizophrenia, informing the continued clinical development of LB-102 for schizophrenia.

Efficacy, Tolerability, and Safety of Xanomeline-Trospium Chloride for Schizophrenia: A Systematic Review and Meta-Analysis

  • Description: [The researchers] conducted a PRISMA 2020-compliant systematic review with random-effects meta-analysis on the efficacy and safety of xanomeline-trospium in randomized controlled trials in patients with schizophrenia.
  • Conclusion: Xanomeline-trospium is an effective treatment for schizophrenia with a unique tolerability profile, potentially addressing unmet needs.

Unmet Social Needs are Associated with Increased Risk and Frequency of Acute Care Utilization in Patients with Schizophrenia Spectrum Disorders

  • Description: This study examined associations between health-related social needs and risk of hospital readmission or emergency department visits within a large academic health system. [The researchers] conducted a retrospective cohort study of 629 adult patients with schizophrenia spectrum disorders discharged from inpatient or ED care between November 2023 and December 2024 at UC San Diego Health.
  • Conclusion: Findings showed that unmet health-related social needs are highly prevalent among schizophrenia spectrum disorders patients and independently predict greater acute care utilization, particularly repeat visits, but not longer length of stay. These results underscore the importance of integrating structured social needs documentation into clinical workflows and leveraging this data for decision support, which may reduce readmissions, improve outpatient engagement, and ultimately lessen health disparities in schizophrenia spectrum disorders.

Clinical Development of LTX-001 a Novel GLS1 Inhibitor for the Treatment of Schizophrenia

  • Description: This was a randomized, double-blinded, placebo-controlled first-in-human study including a single ascending dose part and a multiple ascending dose part in healthy volunteers to assess the safety, tolerability, pharmacokinetics, and pharmacodynamics of LTX-001. Pharmacodynamic endpoints included measurement of plasma glutamine and glutamate levels, as well as functional imaging.
  • Conclusion: Safety, pharmacokinetic, and pharmacodynamic data from this FIH study support the further development of LTX-001 for the treatment of positive, negative and cognitive symptoms of individuals with schizophrenia.

A Novel Repetitive: Transcranial Magnetic Stimulation Protocol for Negative and Cognitive Symptoms of Schizophrenia: A Randomized Controlled Trial

  • Description: Negative and cognitive symptoms in Schizophrenia significantly affect functional outcomes and remain inadequately addressed. Repetitive Transcranial Magnetic Stimulation (rTMS), especially intermittent theta burst stimulation (iTBS), offers a potential therapeutic alternative. This double-blind, randomized, sham-controlled trial evaluated the efficacy and safety of a novel iTBS protocol.
  • Conclusion: The novel iTBS protocol was safe but showed no significant improvement in negative symptoms compared to sham. However, positive trends in cognitive domains like delayed recall, attention and concentration, and recognition suggest potential cognitive benefits.

Look forward to more conference-related content in the coming days. Sign up for alerts and stay informed on the latest published guidelines and articles.